PressRelease

HemoVoid™Enables In-Depth Investigation of the Red Cell Proteome in Chronicobstructive pulmonary disease (COPD)

MONMOUTHJUNCTION, NJ, September 25, 2025–Astudy published in the International Journal of Chronic ObstructivePulmonary Disease entitled “ProteomeProfiling of Red Blood Cells from Patients with COPD Links ProteasomeActivation with Abnormal Cell Morphology and Function”provides an in-depth Red Blood Cell (RBC) proteome profile of chronicobstructive pulmonary disease (COPD). To achieve this, theinvestigators utilized HemoVoid™, BSG’s hemoglobin removalproduct, to perform a comparative proteomic analysis on RBC lysates.

After HemoVoid™ sample prep, totalRBC proteins were analyzed using tandem mass tag (TMT) labelingfollowed by LC-MS/MS. The study identified 160 differentiallyabundant proteins (DAPs) of which 70 were up-regulated, and 90down-regulated in the RBCs of COPD patients. Notably, aprotein-protein interaction (PPI) network analysis revealed a corecomplex of 10 up-regulated proteins that are all components of theproteasome regulatory particle. These upregulated proteasomalproteins represent a novel class of potential blood-based biomarkers.Quantifying these proteins could offer a non-invasive means tomonitor the systemic impact and oxidative stress burden in COPD. Inconclusion, these findings reveal that the systemic pathology of COPDis linked to RBC dysfunction and offer potential new biomarkers andtherapeutic targets.

“Itis very rewarding to see that HemoVoid™ was essential in thisanalysis, as it removed the vast amount of Hemoglobin present in redcells, along with enriching the underlying low abundance proteins. Itis very impressive that the study revealed 160 differentiallyabundant proteins between the two sample sets.” stated Dr. SwapanRoy, President and Founder of Biotech Support Group. “Thishighlights that our products can not only help in improving proteomecoverage, but also quantification.” 

Formore information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of ourHemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.

ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]

Keywords:HemoVoid™, Hemoglobin depletion, Hemoglobin removal, Chronicobstructive pulmonary disease, COPD, red blood cell proteomics,proteasome, erythrocyte proteomics